Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
about
Novel therapeutic targets in chordoma.From notochord formation to hereditary chordoma: the many roles of Brachyury.Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.The molecular aspects of chordoma.Activated c-Abl tyrosine kinase in malignant solid tumors.Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo[Screening key genes associated with the development and progression of non-small cell lung cancer based on gene-enrichment analysis and meta-analysis].Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas
P2860
Q33274528-27876611-E69F-4E61-882D-8C47A3EB1238Q33274793-4961E14D-2E9B-4816-A01D-D3BE3196A8DAQ33275402-0398B037-5003-4960-9459-BDB5DCE5F773Q33275745-47734279-DB55-481B-A25A-72FD68DFAC57Q37129818-A68F8231-883E-43C4-BCF1-804CA46B5533Q41949145-3F44C3B1-8451-4CC5-815F-C172BDE6F926Q55464344-47846016-8A74-418A-9890-19283F02E46CQ57763142-99F42A7A-871B-42C3-89E6-9E7D7418F509
P2860
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
@en
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
@nl
type
label
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
@en
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
@nl
prefLabel
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
@en
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
@nl
P2093
P2860
P50
P356
P1476
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603542
P407
P577
2007-01-01T00:00:00Z